Hyperhidrosis (HH) is a chronic condition that has potential for a debilitating course.

Current treatment modalities for HH are limited with varying side effects.

Systemic anticholinergics have shown benefit in reducing sweat production in HH; however, the associated side effects are limiting factors for use.

Currently, the only approved topical anticholinergic for use in HH is glycopyrronium tosylate.

Topical anticholinergics currently under investigation include oxybutynin, sofpironium bromide, and umeclidinium, each of which has shown a reduction in sweat and anticholinergic-related side effects.